Antibody Binding Capacity for Evaluation of MDR-Related Proteins in Acute Promyclocytic Leukemia: Onset Versus Relapse Expression

Cytometry Part B - Clinical Cytometry

Volumn 59, Issue 1, 2004, Pages 40-45

  Damiani, Daniela ^a   Michieli, Mariagrazia ^b   Michelutti, Angela ^a   Candoni, Anna ^a   Stocchi, Raffaella ^a   Masolini, Paola ^a   Geromin, Antonella ^a   Michelutti, Teresa ^a   Raspadori, Donatella ^c   Ippoliti, Micaela ^c   Lauria, Francesco ^c   Fanin, Renato ^a  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

Author keywords

Acute promyelocytic leukemia; Multidrug resistance related protein; Rescue therapy

Indexed keywords

GLYCOPROTEIN P; LUNG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2;

ADOLESCENT; ADULT; AGED; ANTIGEN BINDING; ARTICLE; BLAST CELL; CALCULATION; CANCER RECURRENCE; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; HUMAN CELL; MALE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; RELAPSE;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEINS; PREDICTIVE VALUE OF TESTS; RECURRENCE; SALVAGE THERAPY;

EID: 2342508454     PISSN: 15524949     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 2003;55:3-29.
2. Sonneveld P, List AF. Chemotherapy resistance in acute myeloid leukaemia. Best Pract Res Clin Haematol 2001;14:211-233.
3. Shtil AA. Emergence of multidrug resistance in leukaemia cells during chemotherapy: mechanisms and prevention. J Hematother Stem Cell Res 2002;11:231-241.
4. Van der Kolk DM, de Vries EGE, Noordhoek L, et al. Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemia. Leukemia 2001;15:1544-1553.
5. Van der Kolk DM, De Vries EGE, Muller M, Vellenga E. The role of drug efflux pumps in acute myeloid leukemia. Leuk Lymphoma 2002;43:685-701.
6. Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998;339:1649-1656.
7. Avvisati G, Lo Coco F, Mandelli F. Acute promyelocytic leukemia: clinical and morphologic features and prognostic factors. Semin Hematol 2001;38:4-12.
8. Avvisati G, Petti MC, Lo Coco F, et al. Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up. Blood 2002;100:3141-3146.
9. Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002;99:759-767.
10. Michieli M, Damiani D, Ermacora A, et al. P-glycoprotein (PGP), lung resistance-related protein (LRP) and multidrug resistance-associated protein (MRP) expression in acute promyelocytic leukemia. Br J Haematol 2000;108:703-709.
11. Paietta E, Anderson J, Racevskis J, Gallagher R, Bennet J, Yunis J, Cassileth P, Wiernik PH. Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: immunological, molecular and functional analyses. Leukemia 1994;8:968-973.
12. Sanz MA, Martin G, Rayon C, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RAR-alpha-positive acute promyelocytic leukemia. Blood 1999;94:3015-3021.
13. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997;337:1021-1028.
14. Lo Coco F, Diverio D, Avvisati G, et al. Therapy of molecular relapse in acute promyelocytic leukemia. Blood 1999;94:2225-2229.
15. Estey EH. Treatment options for relapsed acute promyelocytic leukemia. Best Pract Res Clin Haematol 2003;16:521-534.
16. Kizaki M, Ueno H, Yamazoe Y, et al. Mechanism of retinoid resistance in leukemic cells: possible role of cytochrome 450 and P-glycoprotein. Blood 1996;87:725-733.
17. Takeshita A, Shinjo K, Naito K, et al. Role of P-glycoprotein in all-trans retinoic acid (ATRA) resistance in acute promyelocytic leukaemia cells: analysis of intracellular concentration of ATRA. Br J Haematol 2000;108:90-92.
18. Johnstone RW, Cretney E, Smyth M. P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood 1999;93:1075-1085.
19. Bennet JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 1985;103:626-629.
20. Mistry AR, Pedersen EW, Solomon E, Grimwade D. The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease. Blood Rev 2003;17:71-97.
21. Sanz MA, Lo Coco F, Martin G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000;96:1247-1253.
22. Michieli M, Damiani D, Ermacora A, et al. P-glycoprotein (PGP), lung resistance-related protein (LRP) expression and function in leukaemic blast cells. Br J Haematol 1997;96:356-365.
23. Rainer RO, Hodges L, Seltzer G. CD45 gating correlates with bone marrow differential. Cytometry 1995;22:139-145.
24. Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML/ RAR alpha positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood 1997;90:1014-1021.
25. Scheffer GL, Kool M, Heijn M, et al. Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5 and MDR3 P-glycoprotein with a panel of monoclonal antibodies. Cancer Res 2000;60:5269-5277.
26. Van der Kolk DM, de Vries EGE, Noordhoek L, et al. Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemia. Leukemia 2001;15:1544-1553.
27. Tsuji K, Motoji T, Sugawara I, et al. Significance of lung resistance-related protein in the clinical outcome of acute leukaemic patients with reference to P-glycoprotein. Br J Haematol 2000;110:370-378.
28. Zochbauer S, Gsur A, Brunner R Kyrle PA, Lechner K, Pirker R. P glycoprotein expression as unfavourable prognostic factor in acute myeloid leukemia. Leukemia 1994;8:974-977.
29. Del Poeta G, Stasi R, Aronica G, Venditti A, Cox M, Bruno A, et al. Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. Blood 1996;87:1997-2004.
30. Michieli M, Damiani D, Ermacora A, Masolini P, Raspadori D, Visani G, Scheper RJ, Baccarani M. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocyrtic leukaemias: biological and clinical implications. Br J Haematol 1999;104:328-335.
31. Douer D. Advances in the treatment of relapsed acute promyelocytic leukemia. Acta Haematol 2002;107:1-17.
32. Orfao A, Chillon MC, Bortoluci AM, et al. The flow cytometric pattern of CD34, CD15 and CD13 expression in acute promyeloblastic leukemia is highly characteristic of the presence of PIML-RARalfa gene rearrangements. Haematologica 1999;84:405-412.
33. Murray CK, Estey E, Paietta E, et al. Cd56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome? J Clin Oncol 1999;17:293-297.
34. Slack JL, Willman CL, Andersen JW, et al. Molecular analysis and clinical outcome of adult APL patients with the type V PML-RARalfa isoform: results from intergroup protocol 0129. Blood 2000;95:398-403.
35. Davison K, Mann KK, Miller WH Jr. Arsenic trioxide: mechanism of action. Semin Hematol 2002;39:3-7.
36. Lu DP, Qiu JY, Jiang B, et al. Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood 2002;99:3136-3143.